Ning C Zou

US Patent:

20050197350, Sep 8, 2005

Filed:

Mar 30, 2004

Appl. No.:

10/812075

Inventors:

Yoshinori Sekiguchi - Tokyo, JP
Kosuke Kanuma - Tokyo, JP
Katsunori Omodera - Tokyo, JP
Tsuyoshi Busujima - Tokyo, JP
Thuy-Anh Tran - San Diego CA, US
Sangdon Han - San Diego CA, US
Martin Casper - San Diego CA, US
Bryan Kramer - San Diego CA, US
Graeme Semple - San Diego CA, US
Ning Zou - San Diego CA, US

International Classification:

A61K031/517
A61K031/47
A61K031/513

US Classification:

514266100, 514269000, 514312000, 544285000, 544309000, 546153000

Abstract:

The present invention relates to novel compounds of the Formula (I): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

US Patent:

20090197935, Aug 6, 2009

Filed:

May 17, 2007

Appl. No.:

12/301172

Inventors:

Bradley Teegarden - San Diego CA, US
Dennis Chapman - San Diego CA, US
Juyi Choi - San Diego CA, US
Konrad Feichtinger - San Diego CA, US
Sangdon Han - San Diego CA, US
Honnappa Jayakumar - San Diego CA, US
Thuy-Anh Tran - San Diego CA, US
Jingdong Xu - San Diego CA, US
Ning Zou - San Diego CA, US

Assignee:

ARENA PHARMACEUTICALS, INC. - San Diego CA

International Classification:

A61K 31/415
C07D 231/12
A61P 25/24

US Classification:

514406, 5483751

Abstract:

The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HTserotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HTserotonin receptor associated disorders in combination with other pharmaceutical agents administered separately or together.

US Patent:

20110053958, Mar 3, 2011

Filed:

Mar 17, 2009

Appl. No.:

12/933196

Inventors:

Thuy-Anh Tran - San Diego CA, US
Weichao Chen - San Diego CA, US
Bryan A. Kramer - San Diego CA, US
Abu J.M. Sadeque - San Diego CA, US
Anna Shifrina - San Diego CA, US
Young-Jun Shin - San Diego CA, US
Pureza Vallar - Chula Vista CA, US
Ning Zou - San Diego CA, US

Assignee:

ARENA PHARMACEUTICALS, INC. - San Diego CA

International Classification:

A61K 31/4965
C07C 275/18
C07C 275/28
C07C 271/28
C07C 275/34
C07D 213/75
C07D 333/36
C07D 241/20
C07D 277/48
A61K 31/196
A61K 31/27
A61K 31/4406
A61K 31/381
A61K 31/44
A61K 31/426
A61P 7/02
A61P 9/10
A61P 9/00
A61P 11/06
A61P 3/10
A61P 27/02
A61P 27/06
A61P 9/12
A61P 29/00
A61P 17/06
A61P 19/02
A61P 37/06
A61P 25/28
A61P 11/00

US Classification:

51425506, 562439, 560 27, 546309, 549 69, 544336, 546297, 548195, 514564, 514486, 514488, 514353, 514447, 514349, 514371

Abstract:

The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

US Patent:

20110224262, Sep 15, 2011

Filed:

Nov 24, 2009

Appl. No.:

13/131203

Inventors:

Thuy-Anh Tran - San Diego CA, US
Jason B. Ibarra - Las Vegas NV, US
Young-Jun Shin - San Diego CA, US
Brett Ullman - San Diego CA, US
Ning Zou - San Diego CA, US
Xi Zeng - San Diego CA, US

Assignee:

ARENA PHARMACEUTICALS, INC. - San Diego CA

International Classification:

A61K 31/4439
C07D 231/54
A61K 31/416
C07D 231/10
A61K 31/415
C07D 401/04
C07D 405/04
C07D 409/04
A61K 31/4155
A61P 9/00
A61P 7/02
A61P 11/06
A61P 3/10
A61P 27/06
A61P 27/02
A61P 29/00
A61P 17/06
A61P 9/12
A61P 19/02
A61P 41/00
A61P 21/00
A61P 1/00

US Classification:

514341, 5483591, 5483761, 514406, 5462754, 5483657

Abstract:

Pyrazole derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

US Patent:

20110245251, Oct 6, 2011

Filed:

Dec 7, 2009

Appl. No.:

13/133036

Inventors:

Thuy-Anh Tran - San Diego CA, US
Rena Hayashi - Hacienda Heights CA, US
Jason B. Ibarra - Las Vegas NV, US
Brett Ullman - San Diego CA, US
Ning Zou - San Diego CA, US

Assignee:

Arena Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 31/53
C07D 237/14
C07D 401/04
C07D 409/04
C07D 403/04
C07D 253/07
A61K 31/50
A61K 31/501
C12N 5/071
A61P 9/12
A61P 7/02
A61P 9/00
A61P 9/10
A61P 11/06
A61P 3/10
A61P 13/12
A61P 27/02
A61P 25/02
A61P 27/06
A61P 29/00
A61P 17/06
A61P 19/02
A61P 37/06
A61P 25/28
A61P 17/10
A61P 11/00

US Classification:

514242, 544239, 544238, 544182, 514247, 51425203, 51425205, 51425201, 435375

Abstract:

Cyclohexane derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

US Patent:

20120270861, Oct 25, 2012

Filed:

Mar 9, 2012

Appl. No.:

13/417028

Inventors:

BRADLEY TEEGARDEN - SAN DIEGO CA, US
DENNIS CHAPMAN - SAN DIEGO CA, US
JUYI CHOI - SAN DIEGO CA, US
KONRAD FEICHTINGER - SAN DIEGO CA, US
SANGDON HAN - SAN DIEGO CA, US
HONNAPPA JAYAKUMAR - SAN DIEGO CA, US
JINGDONG XU - SAN DIEGO CA, US
NING ZOU - SAN DIEGO CA, US

International Classification:

C07D 409/12
C07D 413/12
A61K 31/422
C07D 401/12
A61K 31/4439
A61K 31/4709
C07D 403/12
A61K 31/501
C07D 417/12
A61K 31/541
A61K 31/5513
A61P 7/02
A61P 9/00
A61P 9/10
A61P 11/06
A61P 25/00
A61P 25/18
A61P 3/10
A61K 31/4155

US Classification:

514221, 5483657, 514406, 548248, 514378, 5462764, 514341, 546170, 514314, 544238, 51425205, 544 582, 5142278, 540573

Abstract:

The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HTserotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HTserotonin receptor associated disorders in combination with other pharmaceutical agents administered separately or together.

US Patent:

20130217706, Aug 22, 2013

Filed:

Sep 13, 2012

Appl. No.:

13/614326

Inventors:

Thuy-Anh Tran - San Diego CA, US
Weichao Chen - San Diego CA, US
Bryan A. Kramer - San Diego CA, US
Abu J.M. Sadeque - San Diego CA, US
Anna Shifrina - San Diego CA, US
Pureza Vallar - Chula Vista CA, US
Ning Zou - San Diego CA, US

Assignee:

ARENA PHARMACEUTICALS, INC. - San Diego CA

International Classification:

C07C 271/28
C07C 275/28
C07D 277/48
C07D 333/36
C07C 275/34
C07D 241/20
C07C 275/24
C07D 213/75

US Classification:

51425506, 562439, 514564, 560 27, 514488, 546309, 514352, 549 69, 514447, 514486, 544336, 548196, 514371, 435375

Abstract:

The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease; and other diseases.

US Patent:

20220347306, Nov 3, 2022

Filed:

Apr 16, 2019

Appl. No.:

17/048080

Inventors:

- La Jolla CA, US
Junjie LIU - San Diego CA, US
Marcel MIAMPAMBA - San Diego CA, US
Ning ZOU - La Jolla CA, US
Andrew GALE - San Diego CA, US

International Classification:

A61K 47/64
A61K 45/06
A61K 47/65
C07K 7/06
C07K 7/08

Abstract:

Described herein are methods and compositions for the targeted delivery of selective delivery molecule therapeutic agents and imaging agents.